8-K: Rein Therapeutics Announces Change in Independent Registered Public Accounting Firm

Rein Therapeutics replaces Marcum LLP with CBIZ CPAs as its independent registered public accounting firm, effective immediately on April 16, 2025.

Summary

• Rein Therapeutics announced that Marcum LLP resigned as their independent registered public accounting firm, effective immediately on April 16, 2025.
• CBIZ CPAs was engaged as the new independent registered public accounting firm, effective immediately, following approval by the Audit Committee of the Board of Directors.
• Marcum's reports on the company's financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or disclaimer of opinion, but included an explanatory paragraph about the company's ability to continue as a going concern.
• There were no disagreements between Marcum and the company on accounting principles, practices, financial statement disclosure, or audit scope or procedures during the relevant periods.
• The company identified material weaknesses in internal controls related to accounting and supervisory personnel, review of account reconciliations, and timely preparation of financial statements for annual reporting purposes.
• An additional material weakness was identified in 2023 related to the accounting for the acquisition of Lung Therapeutics, Inc.
• The company has authorized Marcum to respond to inquiries from CBIZ CPAs regarding these matters.
• Neither the company nor anyone on its behalf consulted with CBIZ CPAs regarding the application of accounting principles or the type of audit opinion that might be rendered.
• Marcum has provided a letter to the SEC agreeing with the statements made by Rein Therapeutics regarding their resignation.

Sentiment

Score: 3

Explanation: The change in auditors coupled with a going concern warning and material weaknesses in internal controls suggests a negative outlook for the company's financial health.

Positives

• Marcum's reports did not contain an adverse opinion or disclaimer of opinion.
• Marcum agreed with the statements made by Rein Therapeutics regarding their resignation.

Negatives

• Marcum's audit reports for 2023 and 2024 included a going concern warning.
• Material weaknesses were identified in the company's internal controls over financial reporting.

Risks

• The material weaknesses in internal controls could lead to errors in financial reporting.
• The going concern warning from Marcum raises concerns about the company's financial stability.

Industry Context

Changes in accounting firms are not uncommon, but the circumstances surrounding the change, such as the going concern warning and material weaknesses, can raise concerns for investors.

Comparison to Industry Standards

• The presence of a going concern warning is generally viewed negatively and can impact a company's ability to raise capital or secure favorable financing terms.
• Material weaknesses in internal controls are also a concern, as they indicate a higher risk of financial misstatement.
• Companies like BioCryst Pharmaceuticals and Intercept Pharmaceuticals have faced similar scrutiny regarding internal controls and financial reporting in the past.

Stakeholder Impact

• Shareholders may be concerned about the company's financial stability and the potential impact on the stock price.
• Employees may be concerned about job security.
• Creditors may be hesitant to extend credit to the company.

Key Dates

Keywords

accounting firm, Marcum LLP, CBIZ CPAs, independent auditor, internal controls, going concern, Rein Therapeutics, financial reporting